Literature DB >> 27774604

Distribution, physiology and pharmacology of relaxin-3/RXFP3 systems in brain.

Sherie Ma1,2, Craig M Smith1,2,3, Anna Blasiak4, Andrew L Gundlach1,2,5.   

Abstract

Relaxin-3 is a member of a superfamily of structurally-related peptides that includes relaxin and insulin-like peptide hormones. Soon after the discovery of the relaxin-3 gene, relaxin-3 was identified as an abundant neuropeptide in brain with a distinctive topographical distribution within a small number of GABAergic neuron populations that is well conserved across species. Relaxin-3 is thought to exert its biological actions through a single class-A GPCR - relaxin-family peptide receptor 3 (RXFP3). Class-A comprises GPCRs for relaxin-3 and insulin-like peptide-5 and other peptides such as orexin and the monoamine transmitters. The RXFP3 receptor is selectively activated by relaxin-3, whereas insulin-like peptide-5 is the cognate ligand for the related RXFP4 receptor. Anatomical and pharmacological evidence obtained over the last decade supports a function of relaxin-3/RXFP3 systems in modulating responses to stress, anxiety-related and motivated behaviours, circadian rhythms, and learning and memory. Electrophysiological studies have identified the ability of RXFP3 agonists to directly hyperpolarise thalamic neurons in vitro, but there are no reports of direct cell signalling effects in vivo. This article provides an overview of earlier studies and highlights more recent research that implicates relaxin-3/RXFP3 neural network signalling in the integration of arousal, motivation, emotion and related cognition, and that has begun to identify the associated neural substrates and mechanisms. Future research directions to better elucidate the connectivity and function of different relaxin-3 neuron populations and their RXFP3-positive target neurons in major experimental species and humans are also identified. LINKED ARTICLES: This article is part of a themed section on Recent Progress in the Understanding of Relaxin Family Peptides and their Receptors. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.10/issuetoc.
© 2016 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27774604      PMCID: PMC5406293          DOI: 10.1111/bph.13659

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  141 in total

1.  The novel G-protein coupled receptor SALPR shares sequence similarity with somatostatin and angiotensin receptors.

Authors:  M Matsumoto; M Kamohara; T Sugimoto; K Hidaka; J Takasaki; T Saito; M Okada; T Yamaguchi; K Furuichi
Journal:  Gene       Date:  2000-05-02       Impact factor: 3.688

2.  Connections of the nucleus incertus.

Authors:  M Goto; L W Swanson; N S Canteras
Journal:  J Comp Neurol       Date:  2001-09-10       Impact factor: 3.215

3.  Restricted, but abundant, expression of the novel rat gene-3 (R3) relaxin in the dorsal tegmental region of brain.

Authors:  Tanya C D Burazin; Ross A D Bathgate; Mary Macris; Sharon Layfield; Andrew L Gundlach; Geoffrey W Tregear
Journal:  J Neurochem       Date:  2002-09       Impact factor: 5.372

4.  Do centrally administered neuropeptides access cognate receptors?: an analysis in the central corticotropin-releasing factor system.

Authors:  J C Bittencourt; P E Sawchenko
Journal:  J Neurosci       Date:  2000-02-01       Impact factor: 6.167

5.  Anxiolytic action on the behavioural inhibition system implies multiple types of arousal contribute to anxiety.

Authors:  N McNaughton; J A Gray
Journal:  J Affect Disord       Date:  2000-12       Impact factor: 4.839

6.  Human relaxin gene 3 (H3) and the equivalent mouse relaxin (M3) gene. Novel members of the relaxin peptide family.

Authors:  Ross A D Bathgate; Chrishan S Samuel; Tanya C D Burazin; Sharon Layfield; Antonia A Claasz; Irna Grace T Reytomas; Nicola F Dawson; Chongxin Zhao; Courtney Bond; Roger J Summers; Laura J Parry; John D Wade; Geoffrey W Tregear
Journal:  J Biol Chem       Date:  2001-10-31       Impact factor: 5.157

7.  The relaxin receptor-binding site geometry suggests a novel gripping mode of interaction.

Authors:  E E Büllesbach; C Schwabe
Journal:  J Biol Chem       Date:  2000-11-10       Impact factor: 5.157

8.  Distribution of mRNAs encoding CRF receptors in brain and pituitary of rat and mouse.

Authors:  K Van Pett; V Viau; J C Bittencourt; R K Chan; H Y Li; C Arias; G S Prins; M Perrin; W Vale; P E Sawchenko
Journal:  J Comp Neurol       Date:  2000-12-11       Impact factor: 3.215

9.  Protein kinase A mediates the modulation of the slow Ca(2+)-dependent K(+) current, I(sAHP), by the neuropeptides CRF, VIP, and CGRP in hippocampal pyramidal neurons.

Authors:  T Haug; J F Storm
Journal:  J Neurophysiol       Date:  2000-04       Impact factor: 2.714

10.  H3 relaxin is a specific ligand for LGR7 and activates the receptor by interacting with both the ectodomain and the exoloop 2.

Authors:  Satoko Sudo; Jin Kumagai; Shinya Nishi; Sharon Layfield; Tania Ferraro; Ross A D Bathgate; Aaron J W Hsueh
Journal:  J Biol Chem       Date:  2002-12-27       Impact factor: 5.157

View more
  23 in total

1.  Recent progress in the understanding of relaxin family peptides and their receptors.

Authors:  R J Summers
Journal:  Br J Pharmacol       Date:  2017-05       Impact factor: 8.739

2.  Relaxin-3/RXFP3 signalling in mouse hypothalamus: no effect of RXFP3 activation on corticosterone, despite reduced presynaptic excitatory input onto paraventricular CRH neurons in vitro.

Authors:  C Zhang; D V Baimoukhametova; C M Smith; J S Bains; Andrew L Gundlach
Journal:  Psychopharmacology (Berl)       Date:  2017-03-17       Impact factor: 4.530

Review 3.  Dual-transmitter systems regulating arousal, attention, learning and memory.

Authors:  Sherie Ma; Balázs Hangya; Christopher S Leonard; William Wisden; Andrew L Gundlach
Journal:  Neurosci Biobehav Rev       Date:  2017-07-27       Impact factor: 8.989

Review 4.  Modulation of forebrain function by nucleus incertus and relaxin-3/RXFP3 signaling.

Authors:  Francisco E Olucha-Bordonau; Héctor Albert-Gascó; Francisco Ros-Bernal; Valeria Rytova; Emma K E Ong-Pålsson; Sherie Ma; Ana M Sánchez-Pérez; Andrew L Gundlach
Journal:  CNS Neurosci Ther       Date:  2018-05-02       Impact factor: 5.243

5.  Indole-Containing Amidinohydrazones as Nonpeptide, Dual RXFP3/4 Agonists: Synthesis, Structure-Activity Relationship, and Molecular Modeling Studies.

Authors:  Dongliang Guan; Md Toufiqur Rahman; Elaine A Gay; Vineetha Vasukuttan; Kelly M Mathews; Ann M Decker; Alexander H Williams; Chang-Guo Zhan; Chunyang Jin
Journal:  J Med Chem       Date:  2021-12-02       Impact factor: 7.446

Review 6.  Neuropeptides and small-molecule amine transmitters: cooperative signaling in the nervous system.

Authors:  Lee E Eiden; Vito S Hernández; Sunny Z Jiang; Limei Zhang
Journal:  Cell Mol Life Sci       Date:  2022-08-23       Impact factor: 9.207

7.  Discovery and Characterization of the First Nonpeptide Antagonists for the Relaxin-3/RXFP3 System.

Authors:  Elaine A Gay; Dongliang Guan; Kalynn Van Voorhies; Vineetha Vasukuttan; Kelly M Mathews; Joyce Besheer; Chunyang Jin
Journal:  J Med Chem       Date:  2022-05-20       Impact factor: 8.039

8.  Development of a selective agonist for relaxin family peptide receptor 3.

Authors:  Dian Wei; Meng-Jun Hu; Xiao-Xia Shao; Jia-Hui Wang; Wei-Han Nie; Ya-Li Liu; Zeng-Guang Xu; Zhan-Yun Guo
Journal:  Sci Rep       Date:  2017-06-12       Impact factor: 4.379

9.  Effects of chronic silencing of relaxin-3 production in nucleus incertus neurons on food intake, body weight, anxiety-like behaviour and limbic brain activity in female rats.

Authors:  Camila de Ávila; Sandrine Chometton; Sherie Ma; Lola Torz Pedersen; Elena Timofeeva; Carlo Cifani; Andrew L Gundlach
Journal:  Psychopharmacology (Berl)       Date:  2020-01-03       Impact factor: 4.530

10.  Germline and somatic mutations in the pathology of pineal cyst: A whole-exome sequencing study of 93 individuals.

Authors:  Yuanqing Yan; Rebecca Martinez; Maria N Rasheed; Joshua Cahal; Zhen Xu; Yanning Rui; Krista J Qualmann; John P Hagan; Dong H Kim
Journal:  Mol Genet Genomic Med       Date:  2021-05-04       Impact factor: 2.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.